First clinical trial of purified, irradiated malaria sporozoites in humans

Expert Review of Vaccines

Volumn 11, Issue 1, 2012, Pages 31-33

  Daubenberger, Claudia A ^a,b  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

cellular immune reponse; clinical trial; live attenuated sporozoites; nonhuman primate animal model; Plasmodium falciparum

Indexed keywords

PLASMODIUM FALCIPARUM VACCINE; SPOROZOITE VACCINE; UNCLASSIFIED DRUG;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; HUMAN; IMMUNOGENICITY; LIVER; MALARIA; MEMORY T LYMPHOCYTE; MOSQUITO; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; SPOROZOITE;

EID: 83155183288     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.161     Document Type: Article

References (16)

1. Crompton PD, Pierce SK, Miller LH. Advances and challenges in malaria vaccine development. J. Clin. Invest. 120, 4168-4178 (2010).
2. Plotkin SA. Vaccines: past, present and future. Nat. Med. 11, S5-S11 (2005).
3. Kemp DJ, Coppel RL, Cowman AF, Saint RB, Brown GV, Anders RF. Expression of Plasmodium falciparum blood-stage antigens in Escherichia coli: detection with antibodies from immune humans. Proc. Natl Acad. Sci. USA 80, 3787-3791 (1983).
4. Treeck M, Tamborrini M, Daubenberger CA, Gilberger TW, Voss TS. Caught in action: mechanistic insights into antibody-mediated inhibition of Plasmodium merozoite invasion. Trends Parasitol. 25, 494-497 (2009).
5. Luke TC, Hoffman SL. Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. J. Exp. Biol. 206, 3803-3808 (2003). (Pubitemid 37365462)
6. Chattopadhyay R, Conteh S, Li M, James ER, Epstein JE, Hoffman SL. The effects of radiation on the safety and protective efficacy of an attenuated Plasmodium yoelii sporozoite malaria vaccine. Vaccine 27, 3675-3680 (2009).
7. Hoffman SL, Billingsley PF, James E et al. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum. Vaccin. 6, 97-106 (2010).
8. Epstein JE, Tewari K, Lyke KE et al. Live attenuated malaria vaccine designed to protect through hepatic CD8+ T cell immunity. Science 334(6055), 475-480 (2011).
9. Mueller AK, Deckert M, Heiss K, Goetz K, Matuschewski K, Schluter D. Genetically attenuated Plasmodium berghei liver stages persist and elicit sterile protection primarily via CD8 T cells. Am. J. Pathol. 171, 107-115 (2007). (Pubitemid 47339231)
10. Ballou WR. The development of the RTS,S malaria vaccine candidate: challenges and lessons Parasite Immunol. 31, 492-500 (2009).
11. Roestenberg M, McCall M, Hopman J et al. Protection against a malaria challenge by sporozoite inoculation. N. Engl. J. Med. 361, 468-477 (2009).
12. Mueller AK, Labaied M, Kappe SH, Matuschewski K. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 433, 164-167 (2005).
13. Borrmann S, Matuschewski K. Targeting Plasmodium liver stages: better late than never. Trends Mol. Med. 17, 527-536 (2011).
14. Friesen J, Silvie O, Putrianti ED, Hafalla JC, Matuschewski K, Borrmann S. Natural immunization against malaria: causal prophylaxis with antibiotics. Sci. Transl. Med. 2, 40-49 (2010).
15. Robinson T, Campino SG, Auburn S et al. Drug-resistant genotypes and multi-clonality in Plasmodium falciparum analysed by direct genome sequencing from peripheral blood of malaria patients. PLoS One 6, e23204 (2011).
16. Chilengi R. Clinical development of malaria vaccines: should earlier trials be done in malaria endemic countries? Hum. Vaccin. 5, 627-636 (2009).